Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients

• Verfasst von: El-Battrawy, Ibrahim [VerfasserIn]
• Verfasst von: Pilsinger, Christina [VerfasserIn]
• Verfasst von: Liebe, Volker [VerfasserIn]
• Verfasst von: Lang, Siegfried [VerfasserIn]
• Verfasst von: Kuschyk, Jürgen [VerfasserIn]
• Verfasst von: Zhou, Xiao-Bo [VerfasserIn]
• Verfasst von: Borggrefe, Martin [VerfasserIn]
• Verfasst von: Röger, Susanne [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Titel: Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients
• Verf.angabe: Ibrahim El-Battrawy, Christina Pilsinger, Volker Liebe, Siegfried Lang, Jürgen Kuschyk, Xiaobo Zhou, Martin Borggrefe, Susanne Röger and Ibrahim Akin
• E-Jahr: 2019
• Jahr: 2 October 2019
• Umfang: 11 S.
• Fussnoten: Gesehen am 10.12.2019
• Titel Quelle: Enthalten in: Journal of Clinical Medicine
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2019
• Band/Heft Quelle: 8(2019,10) Artikel-Nummer 1582, 11 Seiten
• ISSN Quelle: 2077-0383
• DOI: doi:10.3390/jcm8101582
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: life-threatening arrhythmia
• Sach-SW: sacubitril/valsartan
• Sach-SW: sudden cardiac death
• K10plus-PPN: 1684988551
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Background: Sacubitril/valsartan decreased the risk of sudden cardiac death (SCD) in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, long-term data are sparse. Objective: The aim of the present study was to compare the incidence of life-threatening arrhythmias consisting of ventricular tachycardia and/or ventricular fibrillation before and after initiation of sacubitril/valsartan treatment. Methods: Out of 12,000 patients with HFrEF from 2016&ndash;2018, 148 patients were newly prescribed sacubitril/valsartan, but the long-term data of only 127 patients were available and included in this study. Results: Patients with an average age of 66.8 &plusmn; 12.1 had a median left ventricular ejection fraction (LVEF) of 25% (interquartile range (IQR) 5.00&ndash;45.00) and 30% (IQR 10.00&ndash;55.00, p < 0.0005) before and after sacubitril/valsartan treatment, respectively. Systolic blood pressure decreased from 127.93 &plusmn; 22.01 to 118.36 &plusmn; 20.55 mmHg (p = 0.0035) at 6 months of follow-up. However, in 59 patients with a long-term outcome of 12 months, ventricular arrhythmias persistently increased (ventricular fibrillation from 27.6 to 29.3%, ventricular tachycardia (VT) from 12% to 13.8%, and nonsustained VT from 26.6 to 33.3%). Conclusions: Sacubitril/valsartan does not reduce the risk of ventricular tachyarrhythmias in chronic HFrEF patients over 12 months of follow-up.